Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that having successfully closed an additional financing round, raising CNY63m (~USD10m), it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback